SCHEMBL1986552

SCHEMBL1986552

CC(N)OP(=O)(OC(C)N)OC(C)N

nearest known ligand 0.40

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CTSA P10619 1/20 0.36
ACHE P22303 1/20 0.36
LAP3 P28838 3/20 0.35
METAP1 P53582 1/20 0.32
ANPEP P15144 3/20 0.31
ERAP1 Q9NZ08 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2773546 0.85 ALOX15 (0.34) CTSAACHELAP3
SCHEMBL6014553 0.79 TSHR (0.55) METAP1
SCHEMBL63997 0.75
SCHEMBL1301793 0.73
SCHEMBL11005868 0.73
SCHEMBL5436820 0.73
SCHEMBL1302819 0.73
SCHEMBL5423146 0.73
SCHEMBL5653642 0.73
SCHEMBL5067272 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12145951-B2 Inorganic-organic hybrid compounds including organic platinum-containing anions, for use in medicine KARLSRUHER INSTITUT FUR TECHNOLOGIE (DE) 2024-11-19 US claimed
US-11472898-B2 Method for surface modification of nanoparticles CITY UNIVERSITY OF HONG KONG (HK) 2022-10-18 US claimed
US-20210292353-A1 INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-09-23 US claimed
EP-3829565-A1 INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE Karlsruher Institut für Technologie (DE) 2021-06-09 EP claimed
WO-2020025488-A1 INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE Karlsruher Institut für Technologie (DE) 2020-02-06 WO claimed
US-20110151151-A1 METHOD OF PRODUCING A PRINT MEDIUM NALCO COMPANY 2011-06-23 US claimed
EP-1085909-B1 A complex of alpha-fetoprotein (AFP) and a polyunsaturated fatty acid derivative for the treatment of immune deficiencies ARDENIA INVESTMENTS LTD (GI) 2005-12-28 EP claimed
US-6599507-B2 Immunostimulation ARDENIA INVESTMENTS, LTD. (GI) 2003-07-29 US claimed
US-20010034324-A1 Composition for the treatment of immune deficiencies and methods for its preparation and use OASMIA PHARMACEUTICAL AB (SE) 2001-10-25 US claimed
EP-1085909-A2 COMPOSITION FOR THE TREATEMENT OF IMMUNE DEFICIENCIES AND METHODS FOR ITS PREPARATION AND USE Ardenia Investments Ltd. (GI) 2001-03-28 EP claimed
WO-1999065936-A2 COMPOSITION FOR THE TREATEMENT OF IMMUNE DEFICIENCIES AND METHODS FOR ITS PREPARATION AND USE ARDENIA INVESTMENTS LTD. (GI) 1999-12-23 WO claimed
US-5733787-A COPPER IONS, HYDROPEROXIDE, CHELATING AGENT BAYER CORPORATION (US) 1998-03-31 US claimed
EP-0814335-A2 Method for the detection of creatinine Bayer Corporation (US) 1997-12-29 EP claimed
CN-119113136-A Application of RNAi agent in treating periodontitis and related diseases 北京瑞博开拓医药科技有限公司 2024-12-13 CN disclosed
CN-119095964-A Multi-tail and multi-cap mRNA and uses thereof 博德研究所 2024-12-06 CN disclosed
US-12145951-B2 Inorganic-organic hybrid compounds including organic platinum-containing anions, for use in medicine KARLSRUHER INSTITUT FUR TECHNOLOGIE (DE) 2024-11-19 US disclosed
US-5733787-A COPPER IONS, HYDROPEROXIDE, CHELATING AGENT BAYER CORPORATION (US) 1998-03-31 US disclosed
EP-0537544-A1 Copper oxidation protein assay Bayer Corporation (US) 1993-04-21 EP disclosed
EP-0040039-A1 Ethylene glycol derivatives of ammonioethyl phosphate, their production and use Takeda Chemical Industries, Ltd. (JP) 1981-11-18 EP disclosed
US-4213934-A CORROSION RESISTANCE OF IRON PETROLITE CORPORATION (US) 1980-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034324-A1 Composition for the treatment of immune deficiencies and methods for its preparation and use ALB, NAPEPLD, TTPA CTSA 804/4885ACHE 1794/4885LAP3 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.